TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05769530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine，dexmedetomidine
Description: According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine，dexmedetomidine
Description: According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalbuphine，dexmedetomidine
Description: According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
Study: NCT05895552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 901
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 901
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 901
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 901
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RTA 901-Matching Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RTA 901-Matching Placebo
Description: Administered as specified in the treatment arm.
Study: NCT05510648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: high-intensity laser therapy
Description: A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
Study: NCT04586621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atoldys/ Lexilens - SHAM
Description: Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM- Atoldys/ Lexilens
Description: SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
Study: NCT04670913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: A human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study: NCT05375175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Snack
Description: The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat snack
Description: The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%
Study: NCT05395858

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis using database without any intervention assigned in the study.
Study: NCT05303909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Study: NCT05543148

Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluate hearing loss and communication and conversation disabilities

Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluate hearing loss and communication and conversation disabilities

Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluate hearing loss and communication and conversation disabilities

Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluate hearing loss and communication and conversation disabilities
Study: NCT04813809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BARRIER EasyWarm
Description: Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
Study: NCT05075564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 ES002023
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 ES002023
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study: NCT05813028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a Mobile Application
Description: Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
Study: NCT05063500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol, 25mg/ tablet
Description: Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyene phosphatidylcholine capsules, 228mg/ particle.
Description: Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
Study: NCT05129852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sage oil group
Description: Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reiki group
Description: Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
Study: NCT06105983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir
Description: Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sisunatovir
Description: Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 40 mg
Description: Tablets once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Description: Tablets once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sisunatovir suspension
Description: Tablets once daily for 7 days
Study: NCT05119634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: participants will receive whole body vibration training 3 days in a week and for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home based exercises
Description: participants will receive a home based exercise program for 8 weeks
Study: NCT06105983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir suspension
Description: Tablets once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir suspension
Description: Tablets once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: Tablets once daily for 7 days
Study: NCT05863546

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
Study: NCT05048303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic modified individualized flexible Latarjet procedure
Description: The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
Study: NCT06182020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral functional magnetic stimulation (ISKRA MEDICAL TESLA Former prestige Magneto therapy)
Description: The peripheral functional magnetic stimulation will be conducted 30 minutes a session, 2 sessions per week, for consecutive 8 weeks. The stimulation will be placed over bilateral forearm flexor muscles and bilateral thighs over rectus femoris muscles.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (ENSURE HIGH CALCIUM)
Description: The nutritional supplementation includes 7 cans of ENSURE HIGH CALCIUM per week for 8 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education includes a DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
Study: NCT05791604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG
Description: Take probiotics, 2g each time, twice a day, for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG
Description: Take probiotics, 2g each time, twice a day, for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics with galactomannan and oligofructose
Description: Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
Study: NCT04817007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days
Study: NCT04797130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospital Fit 2.0
Description: HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
Study: NCT06354803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive training
Description: Proprioceptive training using swiss ball for 12 sessions
Study: NCT05640453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
Study: NCT05712330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation samples
Description: machine samples for bacterial culture will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient samples
Description: Patient samples for sputum culture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent questionnaire
Description: parent questionnaire
Study: NCT05960409

Intervention type: PROCEDURE
Intervention: chest tube - emergency thoracotomy
Description: chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients

Intervention type: PROCEDURE
Intervention: chest tube - emergency thoracotomy
Description: chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients

Intervention type: PROCEDURE
Intervention: chest tube - emergency thoracotomy
Description: chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients

Intervention type: PROCEDURE
Intervention: chest tube - emergency thoracotomy
Description: chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients